cytarabine has been researched along with quinazolines in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Grignani, F; Martelli, M; Tonato, M | 1 |
| Marsh, JC | 1 |
| Naito, K; Ohnishi, K | 1 |
| Heinrich, MC; Kampa, KM; Schittenhelm, MM; Yee, KW | 1 |
| Nagpal, S; Riess, J; Wakelee, H | 1 |
| Gwak, HS; Han, JY; Joo, J; Kim, HT; Kim, S; Lee, JS; Lee, SH; Shin, SH; Yoo, H | 1 |
| Negoro, E; Shigemi, H; Ueda, T; Uzui, K; Yamauchi, T; Yoshida, A | 1 |
| Ando, K; Bay, JO; Giagounidis, A; Gröpper, S; Jabbour, EJ; Kantarjian, HM; Martinelli, G; Owen, K; Papayannidis, C; Pike, L; Quintás-Cardama, A; Schmitt, N; Stockman, PK; Wei, A | 1 |
| Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Oliver, SD; Owen, K; Ribrag, V; Rousselot, P; Sekeres, MA; Stockman, PK | 1 |
| Erba, HP | 1 |
| Ashton, S; Barry, ST; Caddy, J; Curtis, NJ; Derbyshire, N; Floc'h, N; Harris, E; Hattersley, M; Jacobs, VN; Maratea, K; Odedra, R; Pease, EJ; Pilling, JE; Taylor, P; Trueman, D; Wen, S | 1 |
| Azimi, A; Goroshchuk, O; Jafari, R; Kolosenko, I; Kunold, E; Palm-Apergi, C; Pirmoradian, M; Vidarsdottir, L | 1 |
2 review(s) available for cytarabine and quinazolines
| Article | Year |
|---|---|
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones | 2015 |
2 trial(s) available for cytarabine and quinazolines
| Article | Year |
|---|---|
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Cytarabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Organophosphates; Protein Serine-Threonine Kinases; Quinazolines; Stomatitis; Treatment Outcome | 2013 |
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Organophosphates; Quinazolines; Treatment Outcome | 2013 |
8 other study(ies) available for cytarabine and quinazolines
| Article | Year |
|---|---|
[Antimetabolites in the therapy of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. I].
Topics: Aminopterin; Antimetabolites; Azaguanine; Cytarabine; DNA, Neoplasm; Humans; Immunity, Cellular; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Purines; Quinazolines; RNA, Neoplasm | 1974 |
Comparative effects of methotrexate, two nonclassic folic acid antagonists, and cytarabine on hematopoietic precursor cells.
Topics: Animals; Cell Survival; Colony-Forming Units Assay; Cytarabine; Dogs; Dose-Response Relationship, Drug; Folic Acid Antagonists; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Methotrexate; Mice; Quinazolines; Species Specificity; Triazines; Trimetrexate | 1982 |
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Proliferation; Cytarabine; Daunorubicin; Drug Synergism; Flow Cytometry; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines | 2009 |
Treatment of leptomeningeal spread of NSCLC: a continuing challenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytarabine; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Meningeal Neoplasms; Methotrexate; Mutation; Pemetrexed; Quinazolines; Radiation Dosage | 2012 |
Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cranial Nerve Diseases; Cytarabine; Erlotinib Hydrochloride; Female; Gefitinib; Headache; Humans; Hydrocortisone; Infusions, Intraventricular; Intracranial Pressure; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mental Disorders; Methotrexate; Middle Aged; Nausea; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vomiting | 2013 |
Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Cell Division; Cell Line, Tumor; Cytarabine; Histones; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Organophosphates; Phosphorylation; Quinazolines; U937 Cells | 2013 |
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Bone Marrow; Cell Line, Tumor; Cytarabine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Nanoparticles; Organophosphates; Polyploidy; Protein Kinase Inhibitors; Quinazolines; Rats; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.
Topics: Antigens, Surface; Cell Cycle Proteins; Cytarabine; Fatty Acids; HL-60 Cells; Humans; Immunity; Jurkat Cells; Leukemia, Myeloid, Acute; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteome; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Quinazolines | 2021 |